STING1 and neoplasm: Combination therapy including STING agonist, anti-PD-1, and anti-CTLA-4 led to significant tumor regression in mice; the Treg cell ratio was suppressed obviously with increased CD8+ T cells in oropharyngeal cancers (Dorta-Estremera et al., 2019).